, Volume 28, Issue 8, pp 705-707
Date: 18 Jul 2013

No evidence of a link between multiple sclerosis and the vaccine against the human papillomavirus

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Cervical lesions due to human papilloma virus (HPV) types 16 and 18 infection are associated with the development of almost 70 % of cervical cancer cases worldwide [1]. The recent introduction of preventive vaccination against papilloma virus will significantly reduce the incidence of cervical cancer. Two virus-like particle (VLP)-based vaccines targeting HPV16 and HPV18 are now offered to adolescent girls and young women among various countries within different vaccine programs [1, 2]. The efficacy of these vaccines in reducing cervical lesions and the safety of this large-scale immunisation in the young adult population has been widely assessed in several clinical trials [1, 2] Furthermore both vaccines were monitored via post licensure safety surveillance study that showed a safety profile broadly consistent with pre marketing studies [1, 2].

More recently, however, cases regarding the onset or exacerbation of multiple sclerosis (MS) following HPV vaccination have been reported, indi ...

Paolo Pellegrino and Carla Carnovale have contributed equally to the work.